Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase

Thrombosis Research

Volumn 88, Issue 2, 1997, Pages 171-181

  Cunningham, Michael A ^a   Blajchman, Morris A ^a,b   Sheffield, William P ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Canadian Red Cross Society   (Canada)

Author keywords

Antithrombin; Elastase; Serpins; Thrombin

Indexed keywords

ANTITHROMBIN; ELASTASE; SERINE PROTEINASE INHIBITOR; THROMBIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELL FREE SYSTEM; ENZYME ANALYSIS; ENZYME SPECIFICITY; GENE MUTATION; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; BINDING SITES; COS CELLS; DRUG INTERACTIONS; HUMANS; LEUKOCYTE ELASTASE; MUTAGENESIS, SITE-DIRECTED; RABBITS; THROMBIN; VARIATION (GENETICS);

EID: 0030698720     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00228-4     Document Type: Article

References (28)

1. ROSENBERG, R.D., and DAMUS, P.S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248, 6490-6505, 1973.
2. HUNT, L.T., and DAYHOFF, M.O. A suprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha-proteinase inhibitor. Biochem Biophys Res Comm 95, 866-871, 1982.
3. HUBER, R., and CARRELL R.W. Implications of the three-dimensional structure of α-1-antirypsin for structure and function of serpins. Biochemistry 28, 8951-8961, 1989.
4. SCHECTER, I., and BERGER, A. On the size of the active site in proteases: (1) Papain. Biochem Biophys Res Comm 27, 157-162, 1967.
5. BJORK, I., JACKSON, C.M., JORNVALL, H., LAVINE, K.K., NORDLING, K., and SALSGIVER, W.J. The active site of antithrombin. J Biol Chem 257, 2406-2411, 1982.
6. OWEN, W.G.. Evidence for the formation of an ester between thrombin and heparin cofactor. Biochim Biophys Acta 405, 380-389, 1975.
7. JORDAN, R.E., OOSTA G.M., GARDNER W.T, and ROSENBERG, R.D. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 255, 10081-10090, 1980.
8. CARRELL, R.W., and OWEN, R.C. Plakalbumin, α-1-antitrysin, antithrombin and the mechanism of inflammatory thrombosis. Nature 317, 730-732, 1985.
9. SHEFFIELD, W.P., BROTHERS, A.B., WELLS, M.J., HATTON, M.W.C., CLARKE, B.J., and BLAJCHMAN, M.A. Molecular cloning and expression of rabbit antithrombin III. Blood 79, 2330-2339, 1992.
10. SHEFFIELD, W.P., and BLAJCHMAN, M.A. Site-directed mutagenesis of the P2 residue of human antithrombin. FEBS Lett 334, 147-150, 1994.
11. SHEFFIELD, W.P., and BLAJCHMAN, M.A. Amino acid substitutions of the P2 residue of human antithrombin that either impair or enhance function. Thromb Res 75, 293-305, 1994.
12. SHEFFIELD, W.P., CASTILLO, J.E., and BLAJCHMAN, M.A. Intracellular events determine the fate of antithrombin Utah. Blood 86, 3461-3467, 1995.
13. CHEN, B., and PRZYBYLA, A.E. An efficient site-directed mutagenesis method based on PCR. Biotechniques 4, 657-658, 1994.
14. AUSUBEL, R.M., BRENT R., KINGSTON, R.E., MOORE, D.D, SEIDMAN J.G., SMITH, J.A., and STRUHL, K. Current Protocols in Molecular Biology, Greene Publishing Associates, Boston, MA, 1989, pp 3.0.3-3.17.5.
15. RAY, F.A., and NICKOLOFF, J.A. Site-specific mutagenesis of almost any plasmid using a PCR-based version of unique site elimination. Biotechniques 13, 342-348, 1992.
16. JORDAN, R.E., KILPATRICK, J., and NELSON, R.M. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 237, 777-779, 1987.
17. HARPER, J.W., COOK. R.R., ROBERTS, J., MCLAUGHLIN, B.J., and POWERS, J.C. Active site mapping of the serine proteases human leukocyte elastase, cathepsin G, porcine pancreatic elastase, rat mast cell proteases I and II, bovine chymotrypsin Aα, and Staphylococcus aureus protease V-8 using tripeptide thiobenzy ester substrates. Biochem 23, 2995-3002, 1984.
18. BODE, W. MEYER, E.E., and POWERS, J.C. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochem 28, 1951-1963, 1989.
19. BLAJCHMAN, M.A., AUSTIN, R.C., FERNANDEZ-RACHUBINSKI, F., and SHEFFIELD, W.P. Molecular basis of inherited antithrombin deficiency. Blood 80, 2159-2171, 1992.
20. STEIN, P.E., and CARRELL, R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct Biol 2, 96-113, 1995.
21. VAN BOECKL, C.A., GROOTENHUIS, P.D., and VISSER, A. A mechanism for heparin-induced potentiation of antithrombin. Nature Struc Biol 1, 423-425, 1994.
22. AUSTIN, R.C., RACHUBINSKI, R.A., FERNANDEZ-RACHUBINSKI, F., and BLAJCHMAN, M.A. Expression in a cell-free system of normal and variant forms of human antithrombin. Ability to bind heparin and react with α-thrombin. Blood 76, 1521-1529, 1990.
23. BODE, W., WEI, A-Z., HUBER, R., MEYER, E., TRAVIS, J., and NEUMANN, S. X-ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor. EMBO J 5, 2543-2458, 1986.
24. 1-antitrypsin. Nature Struc Biol 3, 676-681, 1996.
25. CARRELL, R., SKINNER R., JIN, L., and ABRAHAMS, J.P. Structural mobility of antithrombin and its modulation by heparin. Thromb Haemostas 78, 516-519, 1997.
26. CARRELL, R., EVANS, D.L., and STEIN, P. Mobile reactive centre of serpins and the control of thrombosis. Nature 353: 576-578, 1991.
27. TUCKER, H.M., MOTTONEN, J., GOLDSMITH E.J., and GERARD, R.D. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nature Struc Biol 2, 442-445, 1995.
28. CARRELL, R.W., STEIN, P.E., FERMI, G., and WARDELL, M.R. Biological implications of a 3A structure of dimeric antithrombin. Structure 2, 257-270, 1994.